Canada Markets closed

Braxia Scientific Corp. (BRAX.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.02500.0000 (0.00%)
At close: 02:22PM EDT
Full screen
Previous Close0.0250
Open0.0250
Bid0.0250 x N/A
Ask0.0300 x N/A
Day's Range0.0250 - 0.0250
52 Week Range0.0200 - 0.1000
Volume10,000
Avg. Volume302,862
Market Cap6.018M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateMar 02, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine and Psychedelics Clinical IP

    Toronto, Ontario--(Newsfile Corp. - March 16, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FWB: 4960) ("Braxia", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announces that Irwin Naturals Inc. ("Irwin") has terminated the non-binding amended and restated letter of intent ("LOI") for a business combination between Irwin and Braxia (the "Proposed Transactio

  • Newsfile

    Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin Naturals

    Braxia Health ketamine treatments up 29% YoY in Q3 2023 and revenue up 50.5% YoYToronto, Ontario--(Newsfile Corp. - March 1, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the third

  • Newsfile

    Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement

    Toronto, Ontario--(Newsfile Corp. - February 27, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the "LIFE Offering"), resulting in the issuance of 13,658,524 units of the ..